Search

Your search keyword '"Bochaton T"' showing total 172 results
Start Over Author "Bochaton T"
172 results on '"Bochaton T"'

3. Effects of cannabis on pulmonary arterial pressure in patients hospitalized for acute cardiac events: From the ADDICT-ICCU study

Author

Gonçalves, T., primary, Pezel, T., additional, Fauvel, C., additional, Bauer, F., additional, Ouahidi, A. El, additional, Zakine, C., additional, Bouleti, C., additional, Mansencal, N., additional, Dib, J.C., additional, Goralski, M., additional, Thuaire, C., additional, Bochaton, T., additional, Pommier, T., additional, Lemarchand, L., additional, Meune, C., additional, Delmas, C., additional, Dillinger, J.-G., additional, and Henry, P., additional

Published
2024
Full Text
View/download PDF

4. Prognostic impact of recreational drug use at 1-year follow-up in patients hospitalized for acute cardiovascular events

Author

Pezel, T., primary, Delmas, C., additional, Toupin, S., additional, Bouleti, C., additional, Trimaille, A., additional, Schurtz, G., additional, Pilliero, N., additional, Andrieu, S., additional, Lattuca, B., additional, Rossanaly Vasram, R., additional, Noirclerc, N., additional, Goralski, M., additional, Puymirat, E., additional, Fauvel, C., additional, Roubille, F., additional, Boccara, F., additional, Bochaton, T., additional, Gerbaud, E., additional, Dillinger, J.-G., additional, and Henry, P., additional

Published
2024
Full Text
View/download PDF

5. Prevalence and in-hospital prognostic impact of illicit drug use in patients hospitalized for acute heart failure

Author

Fauvel, C., primary, Bochaton, T., additional, Dillinger, J.-G., additional, El Ouhaidi, A., additional, Zakine, C., additional, Mansencal, N., additional, Noirclerc, N., additional, Goralski, M., additional, Thuaire, C., additional, Lamblin, N., additional, Lim, P., additional, Pommier, T., additional, Lemarchand, L., additional, Henry, P., additional, and Pezel, T., additional

Published
2024
Full Text
View/download PDF

6. Colchicine effect on inflammation biomarkers in acute myocardial infarction

Author

Abou Saleh, I., primary, Leboube, S., additional, Brun, C., additional, Crola Da Silva, C., additional, Hayek, A., additional, Trigon, V., additional, Kaczmarczyk, A., additional, Rioufol, G., additional, Bonnefoy-Cudraz, E., additional, Harbaoui, B., additional, Paillard, M., additional, Bidaux, G., additional, Angoulvant, D., additional, Bochaton, T., additional, and Mewton, N., additional

Published
2024
Full Text
View/download PDF

7. The influence of early post-STEMI inflammation on diastolic function: diagnostic and therapeutic implications

Author

Filip, S, primary, Leboube, S, additional, Thibault, H, additional, Bergerot, C, additional, Paccalaet, A, additional, Hayek, A, additional, Rioufol, G, additional, Bonnefoy-Cudraz, E, additional, Prieur, C, additional, Crola Da Silva, C, additional, Brun, C, additional, Mewton, N, additional, Mechtouff, L, additional, and Bochaton, T, additional

Published
2023
Full Text
View/download PDF

8. Machine-learning score to predict in-hospital outcomes in patients Hospitalized in Intensive Cardiac Care Unit

Author

Weizman, O, primary, Pezel, T, additional, Hamzi, K, additional, Schurtz, G, additional, Hauguel-Moreau, M, additional, Trimaille, A, additional, Toupin, S, additional, Bochaton, T, additional, Attou, S, additional, Meune, C, additional, Boccara, F, additional, Pasdeloup, B, additional, El Ouahidi, Y, additional, Dillinger, J G, additional, and Henry, P, additional

Published
2023
Full Text
View/download PDF

9. Prevalence, Characteristics, and Outcomes of COVID-19-Associated Acute Myocarditis

Author

Ammirati, E, Lupi, L, Palazzini, M, Hendren, N, Grodin, J, Cannistraci, C, Schmidt, M, Hekimian, G, Peretto, G, Bochaton, T, Hayek, A, Piriou, N, Leonardi, S, Guida, S, Turco, A, Sala, S, Uribarri, A, Van De Heyning, C, Mapelli, M, Campodonico, J, Pedrotti, P, Barrionuevo Sanchez, M, Ariza Sole, A, Marini, M, Matassini, M, Vourc'H, M, Cannata, A, Bromage, D, Briguglia, D, Salamanca, J, Diez-Villanueva, P, Lehtonen, J, Huang, F, Russel, S, Soriano, F, Turrini, F, Cipriani, M, Bramerio, M, Di Pasquale, M, Grosu, A, Senni, M, Farina, D, Agostoni, P, Rizzo, S, De Gaspari, M, Marzo, F, Duran, J, Adler, E, Giannattasio, C, Basso, C, Mcdonagh, T, Kerneis, M, Combes, A, Camici, P, De Lemos, J, Metra, M, Ammirati E., Lupi L., Palazzini M., Hendren N. S., Grodin J. L., Cannistraci C. V., Schmidt M., Hekimian G., Peretto G., Bochaton T., Hayek A., Piriou N., Leonardi S., Guida S., Turco A., Sala S., Uribarri A., Van De Heyning C. M., Mapelli M., Campodonico J., Pedrotti P., Barrionuevo Sanchez M. I., Ariza Sole A., Marini M., Matassini M. V., Vourc'H M., Cannata A., Bromage D. I., Briguglia D., Salamanca J., Diez-Villanueva P., Lehtonen J., Huang F., Russel S., Soriano F., Turrini F., Cipriani M., Bramerio M., Di Pasquale M., Grosu A., Senni M., Farina D., Agostoni P., Rizzo S., De Gaspari M., Marzo F., Duran J. M., Adler E. D., Giannattasio C., Basso C., McDonagh T., Kerneis M., Combes A., Camici P. G., De Lemos J. A., Metra M., Ammirati, E, Lupi, L, Palazzini, M, Hendren, N, Grodin, J, Cannistraci, C, Schmidt, M, Hekimian, G, Peretto, G, Bochaton, T, Hayek, A, Piriou, N, Leonardi, S, Guida, S, Turco, A, Sala, S, Uribarri, A, Van De Heyning, C, Mapelli, M, Campodonico, J, Pedrotti, P, Barrionuevo Sanchez, M, Ariza Sole, A, Marini, M, Matassini, M, Vourc'H, M, Cannata, A, Bromage, D, Briguglia, D, Salamanca, J, Diez-Villanueva, P, Lehtonen, J, Huang, F, Russel, S, Soriano, F, Turrini, F, Cipriani, M, Bramerio, M, Di Pasquale, M, Grosu, A, Senni, M, Farina, D, Agostoni, P, Rizzo, S, De Gaspari, M, Marzo, F, Duran, J, Adler, E, Giannattasio, C, Basso, C, Mcdonagh, T, Kerneis, M, Combes, A, Camici, P, De Lemos, J, Metra, M, Ammirati E., Lupi L., Palazzini M., Hendren N. S., Grodin J. L., Cannistraci C. V., Schmidt M., Hekimian G., Peretto G., Bochaton T., Hayek A., Piriou N., Leonardi S., Guida S., Turco A., Sala S., Uribarri A., Van De Heyning C. M., Mapelli M., Campodonico J., Pedrotti P., Barrionuevo Sanchez M. I., Ariza Sole A., Marini M., Matassini M. V., Vourc'H M., Cannata A., Bromage D. I., Briguglia D., Salamanca J., Diez-Villanueva P., Lehtonen J., Huang F., Russel S., Soriano F., Turrini F., Cipriani M., Bramerio M., Di Pasquale M., Grosu A., Senni M., Farina D., Agostoni P., Rizzo S., De Gaspari M., Marzo F., Duran J. M., Adler E. D., Giannattasio C., Basso C., McDonagh T., Kerneis M., Combes A., Camici P. G., De Lemos J. A., and Metra M.

Abstract

Background: Acute myocarditis (AM) is thought to be a rare cardiovascular complication of COVID-19, although minimal data are available beyond case reports. We aim to report the prevalence, baseline characteristics, in-hospital management, and outcomes for patients with COVID-19-associated AM on the basis of a retrospective cohort from 23 hospitals in the United States and Europe. Methods: A total of 112 patients with suspected AM from 56 963 hospitalized patients with COVID-19 were evaluated between February 1, 2020, and April 30, 2021. Inclusion criteria were hospitalization for COVID-19 and a diagnosis of AM on the basis of endomyocardial biopsy or increased troponin level plus typical signs of AM on cardiac magnetic resonance imaging. We identified 97 patients with possible AM, and among them, 54 patients with definite/probable AM supported by endomyocardial biopsy in 17 (31.5%) patients or magnetic resonance imaging in 50 (92.6%). We analyzed patient characteristics, treatments, and outcomes among all COVID-19-associated AM. Results: AM prevalence among hospitalized patients with COVID-19 was 2.4 per 1000 hospitalizations considering definite/probable and 4.1 per 1000 considering also possible AM. The median age of definite/probable cases was 38 years, and 38.9% were female. On admission, chest pain and dyspnea were the most frequent symptoms (55.5% and 53.7%, respectively). Thirty-one cases (57.4%) occurred in the absence of COVID-19-associated pneumonia. Twenty-one (38.9%) had a fulminant presentation requiring inotropic support or temporary mechanical circulatory support. The composite of in-hospital mortality or temporary mechanical circulatory support occurred in 20.4%. At 120 days, estimated mortality was 6.6%, 15.1% in patients with associated pneumonia versus 0% in patients without pneumonia (P=0.044). During hospitalization, left ventricular ejection fraction, assessed by echocardiography, improved from a median of 40% on admission to 55% at discharge

Published
2022

10. P408 PREVALENCE CHARACTERISTICS AND OUTCOMES OF COVID 19 ASSOCIATED ACUTE MYOCARDITIS

Author

Palazzini, M, primary, Ammirati, E, additional, Lupi, L, additional, Giannattasio, C, additional, Soriano, F, additional, Pedrotti, P, additional, Briguglia, D, additional, Mapelli, M, additional, Campodonico, J, additional, Agostoni, P, additional, Leonardi, S, additional, Turco, A, additional, Guida, S, additional, Peretto, G, additional, Sala, S, additional, Camici, P, additional, Marzo, F, additional, Grosu, A, additional, Senni, M, additional, Turrini, F, additional, Bramerio, M, additional, Marini, M, additional, Matassini, M, additional, Rizzo, S, additional, Basso, C, additional, De Gaspari, M, additional, Hendren, N, additional, Schmidt, M, additional, Bochaton, T, additional, Piriou, N, additional, Ubarri, A, additional, Van De Heyning, C, additional, Ariza Sole, A, additional, Cannatà, A, additional, Salamanca, J, additional, Lehtonen, J, additional, Huang, F, additional, Adler, E, additional, and Metra, M, additional

Published
2023
Full Text
View/download PDF

11. Prevalence of illicit drugs use and association with in-hospital major adverse events in patients hospitalised for acute cardiac events: The ADDICT-ICCU Trial

Author

Pezel, T., primary, Dillinger, J.-G., additional, Trimaille, A., additional, Delmas, C., additional, Piliero, N., additional, Bouleti, C., additional, Pommier, T., additional, El Ouahidi, A., additional, Andrieu, S., additional, Lattuca, B., additional, Rossanaly Vasram, R., additional, Noirclerc, N., additional, Schurtz, G., additional, Roubille, F., additional, Fauvel, C., additional, Bochaton, T., additional, Aboyans, V., additional, Puymirat, E., additional, Vicaut, E., additional, and Henry, P., additional

Published
2023
Full Text
View/download PDF

12. Description of intensive cardiac care units (ICCU) in France in 2021: Insight from ADDICT-ICCU registry

Author

Gall, E., primary, Pezel, T., additional, Lattuca, B., additional, Puymirat, E., additional, Hauguel-Moreau, M., additional, Gretzinger, A., additional, Trimaille, A., additional, Léquipar, A., additional, Fauvel, C., additional, Charbonnel, C., additional, Zakine, C., additional, Bedossa, M., additional, Aboyans, V., additional, Deney, A., additional, Schurtz, G., additional, Bouleti, C., additional, Rossanaly Vasram, R., additional, Bochaton, T., additional, Dillinger, J.-G., additional, and Henry, P., additional

Published
2023
Full Text
View/download PDF

16. C75 PHEOCHROMOCYTOMA–INDUCED CARDIOGENIC SHOCK: A MULTICENTER ANALYSIS OF CLINICAL PROFILES, MANAGEMENT AND OUTCOMES

Author

De Angelis, E, primary, Ravera, A, additional, Ammirati, E, additional, Tedeschi, A, additional, Polito, M, additional, Pieroni, M, additional, Gentile, P, additional, Merlo, M, additional, Van De Heyning, C, additional, Bekelaarh, T, additional, Cipriani, A, additional, Camilli, M, additional, Sanna, T, additional, Sinagra, G, additional, Bonnefoy–cudraz, E, additional, Bochaton, T, additional, Hayek, A, additional, and Aloia, A, additional

Published
2022
Full Text
View/download PDF

17. Inflammatory profile and white matter hyperintensity burden in acute ischemic stroke patients

Author

Rascle, L., Nighoghossian, N., Cho, T. H., Bochaton, T., Paccalet, A., Crola da Silva, C., Buisson, Marielle, Amaz, C., Fontaine, J., Ong, E., Derex, L., Berthezene, Y., Eker, O. F., Mewton, N., Ovize, M., Mechtouff, L., Hospices Civils de Lyon (HCL), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre d'Investigation Clinique [Bron] (CIC1407), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupement Hospitalier Est [Bron], Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL], Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and CarMeN, laboratoire

Subjects
Inflammation, [SDV]Life Sciences [q-bio], Immunology, Cerebral small vessel diseases, Magnetic Resonance Imaging, White Matter, Blood biomarkers, Brain Ischemia, Reperfusion injury, [SDV] Life Sciences [q-bio], Stroke, Neurology, Immunology and Allergy, Humans, Neurology (clinical), Biomarkers, Thrombectomy, Ischemic Stroke
Abstract

International audience; Inflammation is involved in small vessel disease (SVD). We aim to clarify whether inflammation related to white matter hyperintensities (WMH), a key component of SVD, may affect the inflammatory response in acute ischemic stroke (AIS) patients. For this, we sequentially measured 10 circulating inflammatory markers and assessed WMH burden on admission MRI in AIS patients treated with thrombectomy. Of 149 patients, 57 (38.3%) had a high WMH burden (Fazekas≥3). A high WMH burden was associated with 4 markers levels but this association did not remain following multivariable analyses. WMH burden is not associated with a specific inflammatory profile in AIS.

Published
2022
Full Text
View/download PDF

18. Prevalence of low health literacy levels in decompensated heart failure compared with acute myocardial infarction patients

Author

Perrin, A., Abdalla, G., Viprey, M., Delahaye, F., Mewton, N., Ovize, M., Sebbag, L., Bochaton, T., Dima, A. L., Bravant, E., Schott, A. M., Haesebaert, J., CarMeN, laboratoire, Research on Healthcare Performance (RESHAPE - Inserm U1290 - UCBL1), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Hospices Civils de Lyon (HCL), Hôpital Louis Pradel [CHU - HCL], Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), and Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)

Subjects
Aged, 80 and over, Heart Failure, Male, lcsh:Diseases of the circulatory (Cardiovascular) system, Epidemiology, [SDV]Life Sciences [q-bio], Myocardial Infarction, Myocardial infarction, Health literacy, Heart failure, Middle Aged, [SDV] Life Sciences [q-bio], Cross-Sectional Studies, Cardiovascular diseases, lcsh:RC666-701, Original Research Articles, Prevalence, Humans, Female, Prospective Studies, Original Research Article, Aged
Abstract

International audience; AIMS: Health literacy (HL) is a health determinant in cardiovascular diseases as the active participation of patients is essential for optimizing self-management of these conditions. We aimed to estimate the prevalence of low HL level in patients hospitalized for acute myocardial infarction (AMI) or acute decompensated heart failure (ADHF) and explore low HL determinants. METHODS AND RESULTS: A prospective cross-sectional study was performed in three cardiology units. HL level was assessed using Brief Health Literacy Screen (BHLS) and categorized as low or adequate. Dimensions of HL were assessed with the Health Literacy Questionnaire (HLQ). Associations with sociodemographic factors, disease history, and comorbidities were explored. A total of 208 patients were included, mean ± SD age was 68.5 ± 14.9 years, and 65.9% were men. Patients with ADHF were significantly older and more often women than AMI patients. Prevalence of low HL was 36% overall, 51% in ADHF patients, and 21% in AMI patients (P \textless 0.001). After adjustment for sociodemographic factors, patients with lower income (€\textless10 000 per year, adjusted odds ratio = 10.46 95% confidence interval [2.38; 54.51], P = 0.003) and native language other than French (adjusted odds ratio = 14.36 95% confidence interval [3.76; 66.9], P \textless 0.002) were more likely to have low HL. ADHF patients presented significantly lower HLQ scores than AMI patients in five out of the nine HLQ dimensions reflecting challenges in access to healthcare. CONCLUSIONS: Prevalence of low HL was higher among ADHF patients than among AMI patients. Low HL ADHF patients needed more support when accessing healthcare services, and these would require more adaptation to respond to low HL patients' needs.

Published
2021
Full Text
View/download PDF

21. Leptin serum level is associated with clinical outcome after STEMI

Author

Paccalet, A., primary, Crola Da Silva, C., additional, Leboube, S., additional, Mechtouff, L., additional, Paillard, M., additional, Amaz, C., additional, Varillon, Y., additional, De Bourguignon, C., additional, Cartier, Y., additional, Prieur, C., additional, Hayek, A., additional, Derimay, F., additional, Rioufol, G., additional, Bonnefoy, C., additional, Mewton, N., additional, Ovize, M., additional, Bidaux, G., additional, and Bochaton, T., additional

Published
2021
Full Text
View/download PDF

22. Matrix Metalloproteinase-9 Relationship With Infarct Growth and Hemorrhagic Transformation in the Era of Thrombectomy

Author

Mechtouff, L., Bochaton, T., Paccalet, A., Crola Da Silva, C., Buisson, M., Amaz, C., Bouin, M., Derex, L., Ong, E., Berthezene, Y., Eker, O. F., Dufay, N., Mewton, N., Ovize, M., Nighoghossian, N., Cho, T. H., Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL], Hospices Civils de Lyon (HCL), Centre d'Investigation Clinique [Bron] (CIC1407), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupement Hospitalier Est [Bron], Hôpital Louis Pradel [CHU - HCL], Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Modeling & analysis for medical imaging and Diagnosis (MYRIAD), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Centre de Recherche et d'Application en Traitement de l'Image et du Signal (CREATIS), Université de Lyon-Université de Lyon-École Supérieure de Chimie Physique Électronique de Lyon (CPE)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Department of Cardiology, Imagerie Tomographique et Radiothérapie, CarMeN, laboratoire, Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL), Imagerie et modélisation Vasculaires, Thoraciques et Cérébrales (MOTIVATE), Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-École Supérieure Chimie Physique Électronique de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Neurology, thrombectomy, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, matrix metalloproteinase 9, Neurology (clinical), stroke, Original Research, MRI, thrombolytic therapy
Abstract

International audience; Objective: To assess the relationship between matrix metalloproteinase 9 (MMP-9), a proteolytic enzyme involved in the breakdown of the blood-brain barrier, and infarct growth and hemorrhagic transformation in acute ischemic stroke (AIS) with large vessel occlusion (LVO) in the era of mechanical thrombectomy (MT) using the kinetics of MMP-9 and sequential magnetic resonance imaging (MRI).Methods: HIBISCUS-STROKE is a cohort study including AIS patients with LVO treated with MT following admission MRI. Patients underwent sequential assessment of MMP-9, follow-up CT at day 1, and MRI at day 6. The CT scan at day 1 classified any hemorrhagic transformation according to the European Co-operative Acute Stroke Study-II (ECASS II) classification. Infarct growth was defined as the difference between final Fluid-Attenuated Inversion Recovery volume and baseline diffusion-weighted imaging volume. Conditional logistic regression analyses were adjusted for main confounding variables including reperfusion status.Results: One hundred and forty-eight patients represent the study population. A high MMP-9 level at 6 h from admission (H6) (p = 0.02), a high glucose level (p = 0.01), a high temperature (p = 0.04), and lack of reperfusion (p = 0.02) were associated with infarct growth. A high MMP-9 level at H6 (p = 0.03), a high glucose level (p = 0.03) and a long delay from symptom onset to groin puncture (p = 0.01) were associated with hemorrhagic transformation.Conclusions: In this MT cohort study, MMP-9 level at H6 predicts infarct growth and hemorrhagic transformation.

Published
2020
Full Text
View/download PDF

23. IL-10 / IL-6 serum ratio as a prognosis marker of STEMI

Author

Leboube, S, primary, Bochaton, T, additional, Paccalet, A, additional, Crola Da Silva, C, additional, Jeantet, P, additional, Amaz, C, additional, De Bourguignon, C, additional, Varillon, Y, additional, Prieur, C, additional, Tomasevic, D, additional, Genot, N, additional, Rioufol, G, additional, Bonnefoy-Cudraz, E, additional, Mewton, N, additional, and Ovize, M, additional

Published
2020
Full Text
View/download PDF

24. Basophil count as a prognosis biomarker after STEMI

Author

Charbonnieras, F., primary, Bochaton, T., additional, Paccalet, A., additional, Jeantet, P., additional, Crola Da Silva, C., additional, Amaz, C., additional, De Bourguignon, C., additional, Prieur, C., additional, Tomasevic, D., additional, Genot, N., additional, Rioufol, G., additional, Bonnefoy-Cudraz, E., additional, Mewton, N., additional, and Ovize, M., additional

Published
2020
Full Text
View/download PDF

26. IL-10/IL-6 serum ratio as a prognosis marker of STEMI

Author

Leboube, S., primary, Bochaton, T., additional, Paccalet, A., additional, Crola Da Silva, C., additional, Jeantet, P., additional, Amaz, C., additional, De Bourguignon, C., additional, Varillon, Y., additional, Prieur, C., additional, Tomasevic, D., additional, Genot, N., additional, Rioufol, G., additional, Bonnefoy-Cudraz, E., additional, Mewton, N., additional, and Ovize, M., additional

Published
2020
Full Text
View/download PDF

30. Association of myocardial edema, hemorrhage and persistent microvascular obstruction with circulating inflammatory biomarkers in acute myocardial infarction patient

Author

Paccalet, A., primary, Bochaton, T., additional, Lassus, J., additional, Derimay, F., additional, Rioufol, G., additional, Prieur, C., additional, Bonnefoy-Cudraz, E., additional, Crola Da Silva, C., additional, Amaz, C., additional, Jossan, C., additional, Monneret, G., additional, Ovize, M., additional, and Mewton, N., additional

Published
2019
Full Text
View/download PDF

32. NAD+ DEPLETION AS A CAUSE OF INFLAMMAGING

Author

Schultz, M B, primary, Bochaton, T, additional, Bonkowski, M, additional, Li, J, additional, Lokitiyakul, D, additional, Colville, A, additional, Gomes, A, additional, and Sinclair, D, additional

Published
2018
Full Text
View/download PDF

33. P1681Daytime variation of infarct size in STEMI patients

Author

Bochaton, T, primary, Bernelin, H, additional, Paccalet, A, additional, Crola Da Silva, C, additional, Baetz, D, additional, Genot, N, additional, Prieur, C, additional, Tomasevic, D, additional, Jossan, C, additional, Amaz, C, additional, Dufay, N, additional, Rioufol, G, additional, Bonnefoy-Cudraz, E, additional, Mewton, N, additional, and Ovize, M, additional

Published
2018
Full Text
View/download PDF

41. Very-Low Threshold for Indication of Temporary RVAD Support in LVAD Recipients: Towards a Monoventricular Philosophy? A Multicentre Experience

Author

Pozzi, M., primary, Robin, J., additional, Grinberg, D., additional, Sebbag, L., additional, Boissonnat, P., additional, Bochaton, T., additional, Sanchez, I., additional, Flamens, C., additional, Paulus, S., additional, Giraud, R., additional, Bendjelid, K., additional, Meyer, P., additional, Licker, M., additional, Banfi, C., additional, Obadia, J., additional, and Kirsch, M., additional

Published
2016
Full Text
View/download PDF

46. Prevalence, Characteristics, and Outcomes of COVID-19-Associated Acute Myocarditis

Author

Enrico Ammirati, Laura Lupi, Matteo Palazzini, Nicholas S. Hendren, Justin L. Grodin, Carlo V. Cannistraci, Matthieu Schmidt, Guillaume Hekimian, Giovanni Peretto, Thomas Bochaton, Ahmad Hayek, Nicolas Piriou, Sergio Leonardi, Stefania Guida, Annalisa Turco, Simone Sala, Aitor Uribarri, Caroline M. Van de Heyning, Massimo Mapelli, Jeness Campodonico, Patrizia Pedrotti, Maria Isabel Barrionuevo Sánchez, Albert Ariza Sole, Marco Marini, Maria Vittoria Matassini, Mickael Vourc’h, Antonio Cannatà, Daniel I. Bromage, Daniele Briguglia, Jorge Salamanca, Pablo Diez-Villanueva, Jukka Lehtonen, Florent Huang, Stéphanie Russel, Francesco Soriano, Fabrizio Turrini, Manlio Cipriani, Manuela Bramerio, Mattia Di Pasquale, Aurelia Grosu, Michele Senni, Davide Farina, Piergiuseppe Agostoni, Stefania Rizzo, Monica De Gaspari, Francesca Marzo, Jason M. Duran, Eric D. Adler, Cristina Giannattasio, Cristina Basso, Theresa McDonagh, Mathieu Kerneis, Alain Combes, Paolo G. Camici, James A. de Lemos, Marco Metra, Ammirati, E, Lupi, L, Palazzini, M, Hendren, N, Grodin, J, Cannistraci, C, Schmidt, M, Hekimian, G, Peretto, G, Bochaton, T, Hayek, A, Piriou, N, Leonardi, S, Guida, S, Turco, A, Sala, S, Uribarri, A, Van De Heyning, C, Mapelli, M, Campodonico, J, Pedrotti, P, Barrionuevo Sanchez, M, Ariza Sole, A, Marini, M, Matassini, M, Vourc'H, M, Cannata, A, Bromage, D, Briguglia, D, Salamanca, J, Diez-Villanueva, P, Lehtonen, J, Huang, F, Russel, S, Soriano, F, Turrini, F, Cipriani, M, Bramerio, M, Di Pasquale, M, Grosu, A, Senni, M, Farina, D, Agostoni, P, Rizzo, S, De Gaspari, M, Marzo, F, Duran, J, Adler, E, Giannattasio, C, Basso, C, Mcdonagh, T, Kerneis, M, Combes, A, Camici, P, De Lemos, J, Metra, M, CarMeN, laboratoire, Niguarda Hospital [Milan, Italy], University of Brescia, University of Texas Southwestern Medical Center [Dallas], Tsinghua University [Beijing] (THU), Center for Systems Biology Dresden [Dresden, Germany] (CSBD), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Universita Vita Salute San Raffaele = Vita-Salute San Raffaele University [Milan, Italie] (UniSR), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hospices Civils de Lyon (HCL), Université de Lyon, unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Università degli Studi di Pavia = University of Pavia (UNIPV), Fondazione IRCCS Policlinico San Matteo [Pavia], Hospital Clinico Universitario de Valladolid [Castilla y León, Spain] (HCUV), Instituto de Salud Carlos III [Madrid] (ISC), University of Antwerp (UA), Università degli Studi di Milano = University of Milan (UNIMI), IRCCS Istituto Nazionale dei Tumori [Milano], Bellvitge University Hospital [Barcelona, Spain], Presidio Ospedaliero 'G. Salesi' AN = Ancona Hospital Salesi [Ancona, Italy] (POGSA-AHS), Hôpital Guillaume-et-René-Laennec [Saint-Herblain], Centre hospitalier universitaire de Nantes (CHU Nantes), Thérapeutiques cliniques et expérimentales des infections (EA 3826) (EA 3826), Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), King‘s College London, King's College Hospital (KCH), Mater Domini Humanitas Hospital [Castellanza, Italy] (MD2H), Hospital Universitario de La Princesa, Helsinki University Hospital [Finland] (HUS), Hôpital Foch [Suresnes], Ospedale Civile di Baggiovara [Modena, Italy] (OCB), Hospital Papa Giovanni XXIII (Hosp P Giovanni XXIII), Azienda Ospedale Università di Padova = Hospital-University of Padua (AOUP), Ospedale 'Infermi' di Rimini [Rimini, Italy] (OIR), University of California [San Diego] (UC San Diego), University of California (UC), and Università degli Studi di Milano-Bicocca = University of Milano-Bicocca (UNIMIB)

Subjects
Adult, Male, outcome, SARS-CoV-2, cardiac, [SDV]Life Sciences [q-bio], Left, COVID-2019, MRI, myocarditis, Female, Humans, Prevalence, Retrospective Studies, Stroke Volume, Ventricular Function, Left, COVID-19, Myocarditis, [SDV] Life Sciences [q-bio], myocarditi, Physiology (medical), Ventricular Function, Human medicine, Cardiology and Cardiovascular Medicine
Abstract

Background: Acute myocarditis (AM) is thought to be a rare cardiovascular complication of COVID-19, although minimal data are available beyond case reports. We aim to report the prevalence, baseline characteristics, in-hospital management, and outcomes for patients with COVID-19–associated AM on the basis of a retrospective cohort from 23 hospitals in the United States and Europe. Methods: A total of 112 patients with suspected AM from 56 963 hospitalized patients with COVID-19 were evaluated between February 1, 2020, and April 30, 2021. Inclusion criteria were hospitalization for COVID-19 and a diagnosis of AM on the basis of endomyocardial biopsy or increased troponin level plus typical signs of AM on cardiac magnetic resonance imaging. We identified 97 patients with possible AM, and among them, 54 patients with definite/probable AM supported by endomyocardial biopsy in 17 (31.5%) patients or magnetic resonance imaging in 50 (92.6%). We analyzed patient characteristics, treatments, and outcomes among all COVID-19–associated AM. Results: AM prevalence among hospitalized patients with COVID-19 was 2.4 per 1000 hospitalizations considering definite/probable and 4.1 per 1000 considering also possible AM. The median age of definite/probable cases was 38 years, and 38.9% were female. On admission, chest pain and dyspnea were the most frequent symptoms (55.5% and 53.7%, respectively). Thirty-one cases (57.4%) occurred in the absence of COVID-19–associated pneumonia. Twenty-one (38.9%) had a fulminant presentation requiring inotropic support or temporary mechanical circulatory support. The composite of in-hospital mortality or temporary mechanical circulatory support occurred in 20.4%. At 120 days, estimated mortality was 6.6%, 15.1% in patients with associated pneumonia versus 0% in patients without pneumonia ( P =0.044). During hospitalization, left ventricular ejection fraction, assessed by echocardiography, improved from a median of 40% on admission to 55% at discharge (n=47; P Conclusions: AM occurrence is estimated between 2.4 and 4.1 out of 1000 patients hospitalized for COVID-19. The majority of AM occurs in the absence of pneumonia and is often complicated by hemodynamic instability. AM is a rare complication in patients hospitalized for COVID-19, with an outcome that differs on the basis of the presence of concomitant pneumonia.

Published
2022
Full Text
View/download PDF

47. (916) - Very-Low Threshold for Indication of Temporary RVAD Support in LVAD Recipients: Towards a Monoventricular Philosophy? A Multicentre Experience.

Author

Pozzi, M., Robin, J., Grinberg, D., Sebbag, L., Boissonnat, P., Bochaton, T., Sanchez, I., Flamens, C., Paulus, S., Giraud, R., Bendjelid, K., Meyer, P., Licker, M., Banfi, C., Obadia, J., and Kirsch, M.

Subjects
*HEART assist devices, *HEART failure treatment, *COMPLICATIONS of artificial hearts, *HEART transplantation, *MEDICAL research, *MEDICAL publishing
Published
2016
Full Text
View/download PDF

48. Effect of ventricular fibrillation on infarct size after myocardial infarction: a translational study.

Author

Stevic N, Pinède A, Mewton N, Ovize M, Argaud L, Lecour S, Boiteux C, Bochaton T, and Cour M

Abstract

Ventricular fibrillation (VF)-induced cardiac arrest frequently complicates ST-segment elevation myocardial infarction (STEMI). Although larger infarct sizes (IS) correlate with a higher risk of VF, the influence of VF itself on IS has remained poorly investigated. To address this knowledge gap, we analyzed the effect of VF on IS in patients and two experimental models. From a prospective cohort, 30 STEMI patients with VF were matched 1:2 with STEMI patients without VF on the common determinants of IS. The primary endpoint was IS, assessed using the 48-h area under the curve (AUC) for troponin. We also compared IS in pigs with/without spontaneous VF during STEMI (n = 15/group), and in an isolated rat heart model of myocardial infarction with/without electrically induced VF (n = 7/group). After matching, the patient characteristics, including the area at risk (AR), were similar. IS was 33% lower in the VF group compared to the control group (troponin AUC 1.6 [0.5-3.3] 10 6 arbitrary units vs. 2.4 [0.9-4.1] 10 6 arbitrary units; p < 0.05), but infarct scar size (assessed using MRI and ECG) did not differ between the groups at 1 and 6 months. In both experimental models, IS, expressed as a percentage of AR, was lower (p < 0.05) in the VF group than in the control group. When common determinants of IS are comparable, VF occurring prior to myocardial infarction reperfusion appears to be associated with smaller IS. Nevertheless, this finding, observed under specific experimental conditions and in a highly selected group of patients, was not associated with reduced infarct scar size.Registration (HIBISCUS-STEMI cohort): ClinicalTrials.gov NCT05794022., Competing Interests: Declarations. Conflict of interests: The authors reports that they have no relationships relevant to the contents of this paper to disclose., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

49. Kinetics and Prognosis Value of CCL5/RANTES at the Acute Phase of ST-Segment-Elevation Myocardial Infarction.

Author

Brun C, Moulin F, Leboube S, Hayek A, Kaczmarczyk A, Saleh IA, Prieur C, Varillon Y, Bonnefoy-Cudraz E, Mewton NO, Bidaux G, Crola Da Silva C, Paillard M, Ducreux S, and Bochaton T

Subjects
Humans, Male, Female, Middle Aged, Prospective Studies, Aged, Prognosis, Time Factors, Severity of Illness Index, Enzyme-Linked Immunosorbent Assay, Predictive Value of Tests, Kinetics, Chemokine CCL5 blood, ST Elevation Myocardial Infarction blood, ST Elevation Myocardial Infarction diagnosis, ST Elevation Myocardial Infarction surgery, Biomarkers blood, Percutaneous Coronary Intervention
Abstract

Background: RANTES (regulated upon activation, normal T cell expressed, and secreted) or CCL5 (CC chemokine ligand 5) is a chemokine that mediates chemotaxis and activation of T cells, monocytes, mast cells, and dendritic cells. It is involved in the pathogenesis of several diseases, including atherosclerosis, but its role at the acute phase of myocardial infarction (MI) is unclear. Our objective is to determine whether the serum level of RANTES is a marker of the severity of acute MI., Methods and Results: The study included 250 consecutive patients with ST-segment-elevation MI who underwent percutaneous coronary intervention in a prospective cohort. Peripheral venous blood samples were taken at 5 time points and ELISA was performed. Major adverse cardiovascular events were prospectively recorded over the 12-month follow-up. Serum RANTES level raised from 12.9 (8.0-20.7) ng/mL at H0 to 13.9 (7.4-22.4) ng/mL at H4 and decreased gradually until 1 month at 9.7 (5.4-13.6) ng/mL ( P <0.0001). RANTES area under the curve (AUC) level was not correlated with infarct size ( r =-0.03, P =0.70) or left ventricular ejection fraction assessed by magnetic resonance imaging ( r =0.02, P =0.80). Patients with a RANTES AUC serum level below the first tertile value of the population (411.0 ng.h.mL -1 ) were more likely to have a major adverse cardiovascular event during the first 12 months after ST-segment-elevation MI (hazard ratio [HR], 2.9 [1.3-6.6], P =0.01). In a multivariable Cox regression analysis, serum level below the first tertile remained associated with an increased risk of experiencing major adverse cardiovascular event during the follow-up (adjusted HR, 2.6 [1.2-5.8], P =0.02)., Conclusions: A low level of circulating RANTES post ST-segment-elevation MI was associated with an increased risk of experiencing major adverse cardiovascular event and might be a valuable prognostic marker in patients with ST-segment-elevation MI.

Published
2024
Full Text
View/download PDF

50. Tricuspid annular plane systolic excursion over systolic pulmonary artery pressure prognostic value for in-hospital adverse events in patients hospitalized for acute coronary syndrome.

Author

Fauvel C, Dillinger JG, Bouleti C, Trimaille A, Tron C, Chaussade AS, Thuaire C, Delmas C, Boccara A, Roule V, Millischer D, Thevenet E, Meune C, Stevenard M, Charbonnel C, Maitre Ballesteros L, Pommier T, El Ouahidi A, Swedsky F, Martinez D, Hauguel-Moreau M, Schurtz G, Coisne A, Dupasquier V, Bochaton T, Gerbaud E, Puymirat E, Henry P, and Pezel T

Subjects
Humans, Male, Female, Aged, Prognosis, Retrospective Studies, Middle Aged, Echocardiography methods, Tricuspid Valve diagnostic imaging, Tricuspid Valve physiopathology, Hospital Mortality, Prospective Studies, France, Hospitalization, Risk Assessment, ROC Curve, Acute Coronary Syndrome diagnostic imaging, Acute Coronary Syndrome physiopathology, Pulmonary Artery diagnostic imaging, Pulmonary Artery physiopathology, Systole
Abstract

Aims: Although several studies have shown that the right ventricular to pulmonary artery (RV-PA) coupling, assessed by the ratio between tricuspid annular plane systolic excursion and systolic pulmonary artery pressure (TAPSE/sPAP) using echocardiography, is strongly associated with cardiovascular events, its prognostic value is not established in acute coronary syndrome (ACS). We aimed to assess the in-hospital prognostic value of TAPSE/sPAP among patients hospitalized for ACS in a retrospective analysis from the prospective ADDICT-ICCU study., Methods and Results: A total of 481 consecutive patients hospitalized in intensive cardiac care unit [mean age 65 ± 13 years, 73% of male, 46% ST-elevation myocardial infarction (STEMI)] for ACS [either STEMI or non-STEMI (NSTEMI)] with TAPSE/sPAP available were included in this prospective French multicentric study (39 centres). The primary outcome was in-hospital major adverse cardiovascular events (MACEs) defined as all-cause death, resuscitated cardiac arrest, or cardiogenic shock and occurred in 33 (7%) patients. Receiver operating characteristic curve analysis identified 0.55 mm/mmHg as the best TAPSE/sPAP cut-off to predict in-hospital MACEs. TAPSE/sPAP <0.55 was associated with in-hospital MACEs, even after adjustment with comorbidities [odds ratio (OR): 19.1, 95% confidence interval (CI) 7.78-54.8], clinical severity including left ventricular ejection fraction (OR: 14.4, 95% CI 5.70-41.7), and propensity-matched population analysis (OR: 22.8, 95% CI 7.83-97.2, all P < 0.001). After adjustment, TAPSE/sPAP <0.55 showed the best improvement in model discrimination and reclassification above traditional prognosticators (C-statistic improvement: 0.16; global χ2 improvement: 52.8; likelihood ratio test P < 0.001) with similar results for both STEMI and NSTEMI subgroups., Conclusion: A low RV-PA coupling defined as TAPSE/sPAP ratio <0.55 was independently associated with in-hospital MACEs and provided incremental prognostic value over traditional prognosticators in patients hospitalized for ACS., Trial Registration: ClinicalTrials.gov Identifier: NCT05063097., Competing Interests: Conflict of interest: None declared., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results